... Aug 01
Latest news updates... Oct 26
Latest pharma news updates... Oct 26
Latest Pharma Update... Aug 23
Every cancer is unique and experience may not be necessarily the same as that of another breast cancer patient. Know some important information about breast ... Aug 19
With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.... Jun 14
Takeover to advance T-Cell Activator Solid Tumor Treatments and expand new Cancer Immunotherapy Portfolio... Mar 13
Pharma collaboration update... Mar 06
EMERCell signs strategic partnership with Onward Therapeutics for the development of its NK cell therapy technology ... Feb 18
BioInvent and Transgene, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of ... Dec 21
This collaboration, which combines KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development... Dec 07
The two partners want to pool their expertise in order to identify and develop new monoclonal antibodies for cancer therapy... Nov 24
The strategic partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support demand for ... Nov 11
PDS Biotech and Farmacore today announced Updates on its co-development program for a Versamune®-based vaccine aimed at preventing COVID-19 infection.... Nov 11
7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines... Nov 09
European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is approved for patients with non-small cell lung cancer in the ... Nov 09
Gritstone Oncology advances into phase 2 expansion cohorts for its personalized neoantigen immunotherapy GRANITE and its off-the-shelf neoantigen immunotherapy SLATE ... Nov 03
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer.... Nov 02
Libtayo is indicated for advanced non-smal cell cancer with PD-L1 Expression of ≥50%... Oct 31
North America Allergy Immunotherapies Market to Forecast to 2027- COVID-19 Impact and Analysis- By Treatment, Allergy type, Distribution Channel and Geography... Oct 28
IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic.... Oct 23
Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers... Oct 07
Manufacturing agreement for Autologous T-Cell Receptor-Based Cell Therapy... Sep 24
... Sep 23
Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung ... Sep 21
-Advertisements-
Friday, May 03, 2024
.jpeg)
